Drug
Ularitide
Ularitide is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated1
Completed1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
terminated133%
completed133%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_2
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
NCT04311489
completedphase_3
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure
NCT01661634
withdrawnphase_1
A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
NCT00487799
Clinical Trials (3)
Showing 3 of 3 trials
NCT04311489Phase 2
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
NCT01661634Phase 3
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure
NCT00487799Phase 1
A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3